Investors are anticipating good news from a potential rival to Alexion’s rare disease blockbuster Soliris, with shares in the company behind it soaring.
Sales of AstraZeneca's COVID-19 vaccine dwindled to almost nothing in the fourth quarter of 2022, contributing to a weaker-than-expected performance for the group.
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved
